Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions
Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP...
Faex Health Announces Investigational AI Screening Capabilities for Ebola and H. pylori, Expanding Gut Health Platform to 18 Conditions